CRISPR

CRISPR1-akr1a1a

ID

ZDB-CRISPR-230519-1

Name

CRISPR1-akr1a1a

Previous Names

None

Target

akr1a1a (1)

Sequence

5' - GGTCAGAGGATGCCAACGG - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

The PAM site was "TGG" at the 3' end.

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
zf3750	akr1a1a

Expression

Gene expression in Wild Types + CRISPR1-akr1a1a

No data available

Phenotype

Phenotype resulting from CRISPR1-akr1a1a

No data available

Phenotype of all Fish created by or utilizing CRISPR1-akr1a1a

Phenotype	Fish	Conditions	Figures
whole organism insrb expression decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	chemical treatment by environment: acrolein	Figure 6 from Qi et al., 2021
whole organism insra expression decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 , Figure 6 from Qi et al., 2021
liver akr1a1a expression absent, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 1 from Qi et al., 2021
whole organism ab3-akt labeling increased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	chemical treatment by environment: acrolein	Figure 7 from Qi et al., 2021
liver insrb expression decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 from Qi et al., 2021
liver acrolein increased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 from Qi et al., 2021
whole organism ab5-akt labeling decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	chemical treatment by environment: acrolein	Figure 7 from Qi et al., 2021
whole organism glucose increased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 from Qi et al., 2021
glomerular basement membrane increased thickness, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 2 from Qi et al., 2021
whole organism ab5-akt labeling decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	control	Figure 7 from Qi et al., 2021
liver phosphofructokinase activity decreased process quality, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 from Qi et al., 2021
hyaloid vessel sprouting angiogenesis increased process quality, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 2 from Qi et al., 2021
hyaloid vessel increased branchiness, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 2 , Figure 6 from Qi et al., 2021
whole organism insrb expression decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 , Figure 6 from Qi et al., 2021
hyaloid vessel increased branchiness, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	chemical treatment by environment: acrolein	Figure 6 from Qi et al., 2021
liver pyruvic acid decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 from Qi et al., 2021
liver insra expression decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 from Qi et al., 2021
whole organism aldo-keto reductase (NADPH) activity decreased process quality, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 1 , Figure 4 from Qi et al., 2021
whole organism insra expression decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	chemical treatment by environment: acrolein	Figure 6 from Qi et al., 2021
whole organism ab3-akt labeling increased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	control	Figure 7 from Qi et al., 2021
blood glucose increased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	food availability	Figure 4 from Qi et al., 2021
whole organism ins expression decreased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 from Qi et al., 2021
whole organism acrolein increased amount, abnormal	akr1a1a^{zf3750/zf3750}; y1Tg	standard conditions	Figure 4 from Qi et al., 2021

Citations